Complete response after chemoradiotherapy for rectal cancer: what is the reasonable approach?
- PMID: 31579765
- PMCID: PMC6754042
- DOI: 10.1515/iss-2017-0041
Complete response after chemoradiotherapy for rectal cancer: what is the reasonable approach?
Abstract
With the increasing use of preoperative treatment rather than upfront surgery, it has become evident that the response of rectal carcinoma to standard chemoradiotherapy (CRT) shows a great variety that includes histopathologiocally confirmed complete tumor regression in 10-30% of cases. Adaptive strategies to avoid radical surgery, either by local excision or non-operative management, have been proposed in these highly responsive tumors. A growing number of prospective clinical trials and experiences from large databases, such as the European Registration of Cancer Care (EURECCA) watch-and-wait database, or the recent Oncological Outcome after Clinical Complete Response in Patients with Rectal Cancer (OnCoRe) project, will provide more information on its safety and efficacy, and help to select appropriate patients. Future studies will have to establish appropriate inclusion criteria and optimize CRT regimens in order to maximize the number of patients achieving complete response. Standardized re-staging procedures have to be investigated to improve the prediction of a sustained complete response, and long-term close follow-up with thorough documentation of failure patterns and salvage therapies will have to prove the oncological safety of this approach.
Keywords: chemoradiotherapy; complete response; local excision; non-operative management; rectal cancer; wait-and-see strategies.
©2018 Rödel C. et al., published by De Gruyter, Berlin/Boston.
Figures


Similar articles
-
Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis.Lancet Oncol. 2016 Feb;17(2):174-183. doi: 10.1016/S1470-2045(15)00467-2. Epub 2015 Dec 17. Lancet Oncol. 2016. PMID: 26705854
-
["Watch and wait" strategy after neoadjuvant therapy for rectal cancer: status survey of perceptions, attitudes and treatment selection in Chinese surgeons].Zhonghua Wei Chang Wai Ke Za Zhi. 2019 Jun 25;22(6):550-559. doi: 10.3760/cma.j.issn.1671-0274.2019.06.008. Zhonghua Wei Chang Wai Ke Za Zhi. 2019. PMID: 31238634 Chinese.
-
[Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].Zhonghua Wei Chang Wai Ke Za Zhi. 2020 Mar 25;23(3):281-288. doi: 10.3760/cma.j.cn.441530-20200228-00096. Zhonghua Wei Chang Wai Ke Za Zhi. 2020. PMID: 32192308 Chinese.
-
Clinical utility of pretreatment prediction of chemoradiotherapy response in rectal cancer: a review.EPMA J. 2017 Mar 3;8(1):61-67. doi: 10.1007/s13167-017-0082-x. eCollection 2017 Mar. EPMA J. 2017. PMID: 28620444 Free PMC article. Review.
-
Factors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in rectal cancer (InterCoRe consortium): an individual participant data meta-analysis.Lancet Gastroenterol Hepatol. 2018 Dec;3(12):825-836. doi: 10.1016/S2468-1253(18)30301-7. Epub 2018 Oct 12. Lancet Gastroenterol Hepatol. 2018. PMID: 30318451
Cited by
-
Cost-Effectiveness of Total Neoadjuvant Therapy With Selective Nonoperative Management for Locally Advanced Rectal Cancer: Analysis of Data From the Organ Preservation for Rectal Adenocarcinoma Trial.J Clin Oncol. 2025 Feb 20;43(6):672-681. doi: 10.1200/JCO.24.00681. Epub 2024 Oct 31. J Clin Oncol. 2025. PMID: 39481074
References
-
- Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow up of 11 years. J Clin Oncol 2012;30:1926–33. - PubMed
- Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C. et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow up of 11 years. J Clin Oncol. 2012;30:1926–33. - PubMed
-
- van Gijn W, Marijnen CA, Nagtegaal ID, Kranenbarg EM-K, Putter H, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 2011;12:575–82. - PubMed
- van Gijn W, Marijnen CA, Nagtegaal ID, Kranenbarg EM-K, Putter H, Wiggers T. et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12:575–82. - PubMed
-
- Fokas E, Liersch T, Fietkau R, Hohenberger W, Beissbarth T, Hess C, et al. Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial after a median follow-up of 11 years. J Clin Oncol 2014;32:1554–62. - PubMed
- Fokas E, Liersch T, Fietkau R, Hohenberger W, Beissbarth T, Hess C. et al. Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial after a median follow-up of 11 years. J Clin Oncol. 2014;32:1554–62. - PubMed
-
- Borschitz T, Wachtlin D, Möhler M, Schmidberger H, Junginger T. Neoadjuvant chemoradiation and local excision for T2-3 rectal cancer. Ann Surg Oncol 2008;15:712–20. - PubMed
- Borschitz T, Wachtlin D, Möhler M, Schmidberger H, Junginger T. Neoadjuvant chemoradiation and local excision for T2-3 rectal cancer. Ann Surg Oncol. 2008;15:712–20. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials